Characteristics of Nigerian women taking sulfadoxine/pyrimethamine twice during pregnancy for the prevention of malaria
2013; Elsevier BV; Volume: 123; Issue: 2 Linguagem: Inglês
10.1016/j.ijgo.2013.05.019
ISSN1879-3479
AutoresNkechi G. Onyeneho, Bright Orji, Joseph Okeibunor, William R. Brieger,
Tópico(s)Poverty, Education, and Child Welfare
ResumoInternational Journal of Gynecology & ObstetricsVolume 123, Issue 2 p. 101-104 Clinical articles Characteristics of Nigerian women taking sulfadoxine/pyrimethamine twice during pregnancy for the prevention of malaria Nkechi G. Onyeneho, Corresponding Author Nkechi G. Onyeneho [email protected] Department of Sociology and Anthropology, University of Nigeria, Nsukka, NigeriaCorresponding author at: Department of Sociology and Anthropology, University of Nigeria, Nsukka, Enugu State, Nigeria. Tel.: + 234 803 68 69451.Search for more papers by this authorBright C. Orji, Bright C. Orji Jhpiego, Uyo, NigeriaSearch for more papers by this authorJoseph C. Okeibunor, Joseph C. Okeibunor Department of Sociology and Anthropology, University of Nigeria, Nsukka, NigeriaSearch for more papers by this authorWilliam R. Brieger, William R. Brieger Johns Hopkins University, Baltimore, USASearch for more papers by this author Nkechi G. Onyeneho, Corresponding Author Nkechi G. Onyeneho [email protected] Department of Sociology and Anthropology, University of Nigeria, Nsukka, NigeriaCorresponding author at: Department of Sociology and Anthropology, University of Nigeria, Nsukka, Enugu State, Nigeria. Tel.: + 234 803 68 69451.Search for more papers by this authorBright C. Orji, Bright C. Orji Jhpiego, Uyo, NigeriaSearch for more papers by this authorJoseph C. Okeibunor, Joseph C. Okeibunor Department of Sociology and Anthropology, University of Nigeria, Nsukka, NigeriaSearch for more papers by this authorWilliam R. Brieger, William R. Brieger Johns Hopkins University, Baltimore, USASearch for more papers by this author First published: 01 August 2013 https://doi.org/10.1016/j.ijgo.2013.05.019Citations: 11Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Abstract Objective To investigate the characteristics of women in Nigeria who are likely to take sulfadoxine/pyrimethamine (SP) as recommended for the prevention of malaria in pregnancy to reduce maternal and child mortality rates. Methods A cross-sectional survey of 1380 women was conducted using a structured questionnaire. The women had given birth within 6 months prior to the survey and were drawn from 6 local government areas in Nigeria. Results Several demographic factors—older age bracket, ever attended school, currently living with a partner, ever married, and wealth—were significantly associated with compliance. Compliance was higher among respondents who had ever been married than among those who had never been married (χ2 = 6.733; P = 0.006). Compliance was also higher among those in paid employment (χ2 = 17.110; P < 0.001) and those in a higher wealth quintile (χ2 = 34.861; P < 0.001). Knowledge of malaria, which included prevention of malaria in pregnancy through use of IPTp with 2 doses of SP, showed a positive association with compliance. Compliance with 2 doses of SP among those with good knowledge was higher (63.9%) than among those with poor knowledge (46.9%) (χ2 = 26.981; P < 0.001). Conclusion The present findings could help in targeting health education programs to specific subgroups of women to increase compliance with the recommended 2 doses of SP for the prevention of malaria in pregnancy. References [1]Shane B. Malaria continues to threaten pregnant women and children. www.popline.org/node/186778, Published December 4, 2001. Accessed November 15, 2012 [2]Steketee R.W., Nahlen B.L., Parise M.E., Menendez C. The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg. 64 (1–2 Suppl.): 2001; 28– 35 [3]Guyatt H.L., Snow R.W. Impact of malaria during pregnancy on low birth weight in sub-Saharan Africa. Clin Microbiol Rev. 17 (4): 2004; 760– 769 [4]Hughes A. Methods to Protect Pregnant Women from Malaria are Still Underutilised in Sub-Saharan Africa. http://www.medicalnewstoday.com/releases/214767.php, Published January 26, 2011. Accessed April 11, 2011 [5] National Population Commission, National Malaria Control Programme, ICF International, Nigeria Malaria Indicator Survey 2010. http://measuredhs.com/pubs/pdf/MIS8/MIS8.pdf, Published January 2012 [6]Okeibunor J.C., Orji B.C., Brieger W., Ishola G., Otolorin E'., Rawlins B., et al. Preventing malaria in pregnancy through community-directed interventions: evidence from Akwa Ibom State, Nigeria. Malar J. 10: 2011; 227 [7] MARA, ARMA, Mapping malaria risk in Africa. http://www.mara.org.za, Published 2004 [8] National Malaria Control Program, National Guidelines and Strategies for Prevention and Control of Malaria during Pregnancy. http://neuroaro.com/sites/default/files/downloadables/NationalguidelinesforMalaria.pdf, Published 2005 [9]Brieger W.R., Otusanya S.A., Oke G.A., Oshiname F.O., Adeniyi J.D. Factors associated with coverage in community-directed treatment with ivermectin for onchocerciasis control in Oyo State, Nigeria. Trop Med Int Health. 7 (1): 2002; 11– 18 [10]Maduka C.U., Nweke L.N., Miri E.S., Amazigo U., Emukah E.C., Richards F.O. Missed treatment opportunities, for pregnant and breast-feeding women, in onchocerciasis mass-treatment programmes in south-eastern Nigeria. Ann Trop Med Parasitol. 98 (7): 2004; 697– 702 [11]Semiyaga N.B., Lalobo O., Ndyomugyenyi R. Refusal to take ivermectin: the associated 'risk' factors in Hoima district, Uganda. Ann Trop Med Parasitol. 99 (2): 2005; 165– 172 [12]Lakwo T.L., Gasarasi D.B. Non-adherence to community directed treatment with ivermectin for onchocerciasis control in Rungwe district, southwest Tanzania. East Afr Med J. 83 (6): 2006; 326– 332 [13]Nuwaha F., Okware J., Ndyomugyenyi R. Predictors of compliance with community-directed ivermectin treatment in Uganda: quantitative results. Trop Med Int Health. 10 (7): 2005; 659– 667 Citing Literature Volume123, Issue2November 2013Pages 101-104 ReferencesRelatedInformation
Referência(s)